Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2018-12-07 | RTRX | Retrophin, Inc. | Aselage Steve | CEO | S - Sale | $24.04 | -10 | 251,523 | 0% | -$240 | ||||||
2018-12-06 | DVAX | Dynavax Technologies Corp | Cano Francis | Dir | S - Sale | $10.47 | -2,000 | 0 | -100% | -$20,942 | ||||||
| DM | 2018-12-04 | AMPH | Amphastar Pharmaceuticals, Inc. | Lee Howard | Dir | S - Sale+OE | $21.67 | -29,278 | 123,381 | -19% | -$634,464 | |||||
2018-12-06 | APVO | Aptevo Therapeutics Inc. | Maddux Randy Joe | SVP Operations | P - Purchase | $2.37 | +5,000 | 30,000 | +20% | +$11,850 | ||||||
2018-12-04 | NEOS | Neos Therapeutics, Inc. | McLaughlin Gerald W. | CEO | P - Purchase | $2.04 | +7,403 | 7,403 | New | +$15,120 | ||||||
| M | 2018-12-06 | BTAI | Bioxcel Therapeutics, Inc. | Mueller Peter | Dir | P - Purchase | $5.01 | +8,795 | 158,320 | +6% | +$44,045 | |||||
| D | 2018-12-06 | SPPI | Spectrum Pharmaceuticals Inc | Maida Anthony E III | Dir | S - Sale+OE | $12.60 | -7,250 | 32,988 | -18% | -$91,350 | |||||
| D | 2018-12-04 | ABBV | Abbvie Inc. | Schumacher Laura J | EVP | S - Sale+OE | $93.58 | -94,140 | 98,258 | -49% | -$8,809,552 | |||||
2018-12-06 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $7.50 | -4,000 | 156,188 | -2% | -$29,988 | ||||||
2018-12-06 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale | $7.38 | -1,500 | 87,067 | -2% | -$11,070 | ||||||
2018-11-23 | MBIO | Mustang Bio, Inc. | Herskowitz Neil | Dir | P - Purchase | $3.96 | +1,000 | 71,000 | +1% | +$3,960 | ||||||
| D | 2018-12-06 | ITCI | Intra-Cellular Therapies, Inc. | Davis Robert E | SVP, Chief Scientific Officer | S - Sale+OE | $13.53 | -899 | 30,256 | -3% | -$12,163 | |||||
| M | 2018-12-04 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.03 | +26,600 | 26,313,698 | 0% | +$782 | |||||
2018-12-06 | AQST | Aquestive Therapeutics, Inc. | Maxwell John T. | SVP-CFO | P - Purchase | $8.87 | +5,000 | 153,614 | +3% | +$44,350 | ||||||
2018-12-07 | RARE | Ultragenyx Pharmaceutical Inc. | Aliski William | Dir | S - Sale | $49.69 | -6,000 | 162,960 | -4% | -$298,140 | ||||||
| D | 2018-12-06 | GTHX | G1 Therapeutics, Inc. | Moses Jennifer K. | VP of Finance, Admin | S - Sale+OE | $34.00 | -750 | 4,000 | -16% | -$25,500 | |||||
2018-12-05 | NATR | Natures Sunshine Products Inc | Hughes Kristine F | Dir | S - Sale | $9.01 | -3,000 | 656,722 | 0% | -$27,030 | ||||||
| M | 2018-12-03 | ARPO | Aerpio Pharmaceuticals, Inc. | Satter Muneer A | Dir, 10% | P - Purchase | $2.09 | +60,000 | 5,198,017 | +1% | +$125,352 | |||||
| M | 2018-12-03 | EIDX | Eidos Therapeutics, Inc. | Bridgebio Pharma LLC | 10% | P - Purchase | $14.92 | +2,853,848 | 22,468,503 | +15% | +$42,589,910 | |||||
| D | 2018-12-06 | FGEN | Fibrogen Inc | Neff Thomas B | CEO | S - Sale+OE | $40.93 | -30,000 | 2,790,681 | -1% | -$1,227,776 | |||||
| D | 2018-12-03 | MYOK | Myokardia Inc | Lee June | See Remarks | S - Sale+OE | $60.81 | -5,000 | 770 | -87% | -$304,060 | |||||
| DM | 2018-12-04 | TXMD | Therapeuticsmd, Inc. | Milligan John C.K. IV | Pres, Secretary | S - Sale+OE | $4.77 | -258,000 | 5,464,606 | -5% | -$1,231,692 | |||||
| M | 2018-12-03 | KURA | Kura Oncology, Inc. | Ecor1 Capital Fund Qualified, L.P. | 10% | P - Purchase | $13.50 | +119,906 | 4,180,919 | +3% | +$1,618,255 | |||||
| M | 2018-12-03 | ICPT | Intercept Pharmaceuticals, Inc. | Bright Lisa | Pres, International | S - Sale | $111.42 | -5,000 | 21,288 | -19% | -$557,121 | |||||
| D | 2018-12-03 | ALKS | Alkermes Plc. | Mitchell Paul J | Dir | S - Sale+OE | $36.45 | -1,000 | 8,000 | -11% | -$36,450 | |||||
2018-12-04 | BDSI | Biodelivery Sciences International Inc | De Paolantonio Ernest Robert | CFO, Secretary, Treasurer | S - Sale | $3.79 | -16,161 | 140,548 | -10% | -$61,250 | ||||||
2018-12-03 | PRVB | Provention Bio, Inc. | Digiandomenico Anthony | Dir | P - Purchase | $2.45 | +4,442 | 29,442 | +18% | +$10,883 | ||||||
| M | 2018-12-04 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, COB, CEO, 10% | P - Purchase | $0.24 | +3,000 | 6,517,834 | 0% | +$730 | |||||
2018-12-06 | CLSD | Clearside Biomedical, Inc. | Thorp Clay | Dir, 10% | P - Purchase | $1.36 | +8,000 | 3,474,394 | 0% | +$10,880 | ||||||
2018-12-04 | BTAI | Bioxcel Therapeutics, Inc. | Mueller Peter | Dir | P - Purchase | $5.13 | +4,007 | 149,525 | +3% | +$20,544 | ||||||
| DM | 2018-12-03 | JNJ | Johnson & Johnson | Fasolo Peter | EVP, CHRO | S - Sale+OE | $146.41 | -166,695 | 78,327 | -68% | -$24,405,241 | |||||
| D | 2018-12-03 | ZTS | Zoetis Inc. | Chen Heidi C. | EVP | S - Sale+OE | $93.51 | -2,500 | 17,662 | -12% | -$233,775 | |||||
| D | 2018-12-04 | CLVS | Clovis Oncology, Inc. | Rolfe Lindsey | See Remarks | S - Sale+OE | $21.23 | -284 | 14,162 | -2% | -$6,029 | |||||
2018-12-04 | CFRX | Contrafect Corp | Fosun Industrial Co., Ltd | 10% | S - Sale | $2.04 | -600,000 | 7,900,000 | -7% | -$1,224,000 | ||||||
2018-12-04 | CFRX | Contrafect Corp | Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 10% | S - Sale | $2.04 | -600,000 | 7,900,000 | -7% | -$1,224,000 | ||||||
| D | 2018-12-04 | CLVS | Clovis Oncology, Inc. | Ivers-Read Gillian C | See Remarks | S - Sale+OE | $21.23 | -250 | 186,152 | 0% | -$5,308 | |||||
| D | 2018-12-04 | CLVS | Clovis Oncology, Inc. | Muehl Daniel W | See Remarks | S - Sale+OE | $21.23 | -188 | 5,664 | -3% | -$3,991 | |||||
| M | 2018-11-29 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres | P - Purchase | $0.03 | +34,100 | 26,287,098 | 0% | +$964 | |||||
2018-12-03 | JAZZ | Jazz Pharmaceuticals Plc | Cozadd Bruce C | COB, CEO | S - Sale | $151.78 | -1,000 | 277,688 | 0% | -$151,780 | ||||||
2018-12-03 | BHVN | Biohaven Pharmaceutical Holding Co Ltd. | Doogan Declan | Dir | S - Sale | $41.95 | -40,000 | 1,619,915 | -2% | -$1,678,000 | ||||||
2018-12-03 | CARA | Cara Therapeutics, Inc. | Menzaghi Frederique Ph.D. | SVP-Research, Development | S - Sale | $18.36 | -3,000 | 139,000 | -2% | -$55,080 | ||||||
2018-12-03 | CARA | Cara Therapeutics, Inc. | Chalmers Derek T | Pres, CEO | S - Sale | $18.17 | -20,000 | 971,392 | -2% | -$363,400 | ||||||
2018-12-04 | CRVS | Corvus Pharmaceuticals, Inc. | Miller Richard A Md | Pres, CEO | P - Purchase | $5.95 | +1,502 | 1,113,795 | 0% | +$8,937 | ||||||
2018-12-03 | RYTM | Rhythm Pharmaceuticals, Inc. | Gottesdiener Keith Michael | CEO, Pres | S - Sale | $30.00 | -563 | 571,476 | 0% | -$16,890 | ||||||
| D | 2018-12-03 | ARRY | Array Biopharma Inc | Sandor Victor | Chief Medical Officer | S - Sale+OE | $16.21 | -115,185 | 222,298 | -34% | -$1,867,045 | |||||
2018-12-03 | AMPH | Amphastar Pharmaceuticals, Inc. | Zhou Rong | EVP, Production Center | S - Sale | $22.00 | -1,089 | 157,787 | -1% | -$23,958 | ||||||
| D | 2018-12-03 | AMPH | Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | Pres, GC | S - Sale+OE | $22.44 | -16,630 | 183,815 | -8% | -$373,177 | |||||
2018-12-04 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $119.00 | -15,500 | 118,015,304 | 0% | -$1,844,536 | ||||||
2018-11-06 | NATR | Natures Sunshine Products Inc | Hughes Kristine F | Dir | S - Sale | $9.23 | -3,000 | 659,722 | 0% | -$27,690 | ||||||
2018-12-04 | APVO | Aptevo Therapeutics Inc. | White Marvin L | Pres, CEO | P - Purchase | $2.38 | +10,000 | 203,603 | +5% | +$23,800 | ||||||
2018-12-03 | QURE | Uniqure N.V. | Astley-Sparke Philip | Dir | S - Sale | $30.39 | -5,000 | 23,252 | -18% | -$151,950 | ||||||
2018-12-04 | PHAS | Phasebio Pharmaceuticals Inc | Thorp Clay | Dir, 10% | P - Purchase | $3.13 | +4,000 | 2,473,848 | 0% | +$12,520 | ||||||
| D | 2018-12-03 | ISCO | International Stem Cell Corp | Kern Russell | EVP, CSO, 10% | S - Sale+OE | $1.67 | -1,800 | 178,398 | -1% | -$3,006 | |||||
| D | 2018-12-04 | ISCO | International Stem Cell Corp | Garnette Sophia | VP, Legal Affairs, Operations | S - Sale+OE | $1.54 | -10,636 | 267 | -98% | -$16,379 | |||||
2018-12-03 | IMMY | Imprimis Pharmaceuticals, Inc. | Kammer Robert J | Dir | S - Sale | $4.64 | -10,000 | 889,827 | -1% | -$46,400 | ||||||
| M | 2018-12-03 | BTAI | Bioxcel Therapeutics, Inc. | Yocca Frank | Chief Scientific Officer | P - Purchase | $5.21 | +900 | 1,850 | +95% | +$4,692 | |||||
| D | 2018-12-03 | ANAB | Anaptysbio Inc | Piscitelli Dominic | CFO | S - Sale+OE | $72.14 | -37,000 | 0 | -100% | -$2,669,158 | |||||
| D | 2018-12-03 | AMPH | Amphastar Pharmaceuticals, Inc. | Peters William J | CFO, SVP, Treasurer | S - Sale+OE | $22.40 | -10,000 | 78,795 | -11% | -$224,001 | |||||
| DM | 2018-11-30 | TXMD | Therapeuticsmd, Inc. | Bernick Brian | Dir | S - Sale+OE | $5.07 | -182,800 | 6,802,371 | -3% | -$926,796 | |||||
2018-12-03 | KIN | Kindred Biosciences, Inc. | Chin Richard | CEO, 10% | S - Sale | $13.28 | -40,000 | 1,946,071 | -2% | -$531,200 | ||||||
| D | 2018-12-03 | ALDR | Alder Biopharmaceuticals Inc | Smith Jeffrey T L | MD | S - Sale+OE | $13.84 | -5,044 | 831 | -86% | -$69,826 | |||||
| DM | 2018-11-30 | CERC | Cerecor Inc. | Armistice Capital, LLC | Dir, 10% | P - Purchase | $3.49 | +25,797 | 36,007,200 | 0% | +$90,153 | |||||
| D | 2018-12-04 | GTHX | G1 Therapeutics, Inc. | Rudnick Seth | Dir | S - Sale+OE | $39.31 | -10,000 | 58,282 | -15% | -$393,146 | |||||
2018-12-03 | BDSI | Biodelivery Sciences International Inc | Odonnell Francis E Jr | Dir | S - Sale | $3.72 | -8,000 | 514,187 | -2% | -$29,760 | ||||||
2018-11-30 | ITRM | Iterum Therapeutics Plc | Kelly David George | Dir | P - Purchase | $6.29 | +10,000 | 19,548 | +105% | +$62,887 | ||||||
2018-12-03 | BGNE | Beigene, Ltd. | Wang Xiaodong | Dir | S - Sale | $152.41 | -5,000 | 12,932,980 | 0% | -$762,061 | ||||||
2018-12-04 | BTAI | Bioxcel Therapeutics, Inc. | Mehta Vimal | CEO, Pres, Secretary | P - Purchase | $5.12 | +1,000 | 3,000 | +50% | +$5,120 | ||||||
| D | 2018-11-30 | ACAD | Acadia Pharmaceuticals Inc | Baker Bros. Advisors LP | Dir, 10% | P - Purchase | $17.00 | +11,764,705 | 71,647 | -101% | +$199,999,985 | |||||
2018-12-03 | PBYI | Puma Biotechnology, Inc. | Eyler Charles R | SEE REMARKS | S - Sale | $22.77 | -1,239 | 33,967 | -4% | -$28,212 | ||||||
2018-11-30 | MSLP | Musclepharm Corp | Wynnefield Partners Small Cap Value LP I | 10% | P - Purchase | $0.90 | +7,000 | 1,681,305 | 0% | +$6,270 | ||||||
| D | 2018-12-03 | VRTX | Vertex Pharmaceuticals Inc / Ma | Silva Paul M | SVP, Corp Controller | S - Sale+OE | $186.52 | -809 | 16,256 | -5% | -$150,895 | |||||
| D | 2018-12-03 | ASRT | Assertio Therapeutics, Inc | Dawes Karen A | Dir | S - Sale+OE | $4.84 | -8,421 | 42,089 | -17% | -$40,725 | |||||
2018-12-03 | BTAI | Bioxcel Therapeutics, Inc. | Mehta Vimal | CEO, Pres, Secretary | P - Purchase | $5.17 | +1,000 | 2,000 | +100% | +$5,165 | ||||||
2018-12-03 | BTAI | Bioxcel Therapeutics, Inc. | Steinhart Richard I | CFO | P - Purchase | $5.20 | +500 | 1,500 | +50% | +$2,600 | ||||||
| D | 2018-11-30 | TEVA | Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun | EVP, Global R, D | S - Sale+OE | $21.76 | -933 | 8,829 | -10% | -$20,304 | |||||
| D | 2018-11-30 | AMPH | Amphastar Pharmaceuticals, Inc. | Liawatidewi Yakob | SVP Corp Admin Center | S - Sale+OE | $21.50 | -13,980 | 43,832 | -24% | -$300,513 | |||||
2018-11-30 | INNT | Innovate Biopharmaceuticals, Inc. | Proujansky Roy | Dir | P - Purchase | $2.63 | +1,400 | 1,400 | New | +$3,682 | ||||||
2018-11-30 | INNT | Innovate Biopharmaceuticals, Inc. | Laumas Sandeep | Exec COB | P - Purchase | $2.63 | +3,000 | 766,373 | 0% | +$7,890 | ||||||
| M | 2018-11-29 | PRVB | Provention Bio, Inc. | Digiandomenico Anthony | Dir | P - Purchase | $2.45 | +5,000 | 25,000 | +25% | +$12,253 | |||||
| D | 2018-12-03 | GTHX | G1 Therapeutics, Inc. | Murdock Terry L | SVP of Development Operations | S - Sale+OE | $38.54 | -3,523 | 0 | -100% | -$135,779 | |||||
| M | 2018-11-28 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres, COB, CEO, 10% | P - Purchase | $0.25 | +24,000 | 6,550,360 | 0% | +$5,935 | |||||
2018-11-29 | ICPT | Intercept Pharmaceuticals, Inc. | Micheli Francesco | 10% | S - Sale | $105.07 | -750,000 | 6,095,578 | -11% | -$78,802,500 | ||||||
2018-11-29 | ICPT | Intercept Pharmaceuticals, Inc. | Genextra S.P.A. | 10% | S - Sale | $105.07 | -750,000 | 6,095,578 | -11% | -$78,802,500 | ||||||
2018-11-29 | EOLS | Evolus, Inc. | Blank Simone | Dir | P - Purchase | $14.00 | +295,024 | 295,024 | New | +$4,130,336 | ||||||
2018-11-29 | EOLS | Evolus, Inc. | Romine Kristine | Dir | P - Purchase | $14.00 | +6,347 | 24,347 | +35% | +$88,858 | ||||||
2018-11-30 | ZTS | Zoetis Inc. | Reed Willie M | Dir | S - Sale | $93.74 | -3,205 | 566 | -85% | -$300,437 | ||||||
| DM | 2018-11-29 | ATNX | Athenex, Inc. | Zhang Song-Yi | Dir | S - Sale+OE | $13.15 | -1,000,000 | 5,317,721 | -16% | -$13,152,000 | |||||
2018-11-21 | AQST | Aquestive Therapeutics, Inc. | Marshall Ken W. | Commercial Leader | P - Purchase | $10.15 | +1,445 | 1,445 | New | +$14,667 | ||||||
| M | 2018-11-16 | MBIO | Mustang Bio, Inc. | Achenbach Brian | VP, Fin., Corp. Controller | P - Purchase | $4.20 | +2,500 | 57,500 | +5% | +$10,497 | |||||
| M | 2018-11-28 | ARPO | Aerpio Pharmaceuticals, Inc. | Satter Muneer A | Dir, 10% | P - Purchase | $1.98 | +60,000 | 5,138,017 | +1% | +$118,524 | |||||
2018-11-26 | STML | Stemline Therapeutics Inc | Hoberman Kenneth | COO | S - Sale | $11.85 | -26,296 | 659,738 | -4% | -$311,608 | ||||||
| DM | 2018-11-28 | TXMD | Therapeuticsmd, Inc. | Milligan John C.K. IV | Pres, Secretary | S - Sale+OE | $4.96 | -258,128 | 5,464,606 | -5% | -$1,280,324 | |||||
| D | 2018-11-30 | AMRN | Amarin Corp Plcuk | Ketchum Steven B | Chief Scientific Officer | S - Sale+OE | $17.79 | -17,042 | 341,297 | -5% | -$303,174 | |||||
| D | 2018-11-30 | AMRN | Amarin Corp Plcuk | Kennedy Joseph T | GC | S - Sale+OE | $17.81 | -23,306 | 217,934 | -10% | -$414,998 | |||||
2018-11-30 | CLRB | Cellectar Biosciences, Inc. | Caruso James V | Pres, CEO | P - Purchase | $2.28 | +1,000 | 22,354 | +5% | +$2,282 | ||||||
| D | 2018-11-29 | CLRB | Cellectar Biosciences, Inc. | Hill Stephen A | Dir | S - Sale+OE | $2.21 | -992 | 0 | -100% | -$2,192 | |||||
2018-11-28 | ALXN | Alexion Pharmaceuticals, Inc. | Franchini Indrani Lall | EVP, Chief Compliance Officer | S - Sale | $118.13 | -2,605 | 29,304 | -8% | -$307,729 | ||||||
2018-11-30 | BTAI | Bioxcel Therapeutics, Inc. | Steinhart Richard I | CFO | P - Purchase | $5.00 | +500 | 1,000 | +100% | +$2,500 | ||||||
2018-11-30 | BTAI | Bioxcel Therapeutics, Inc. | Yocca Frank | Chief Scientific Officer | P - Purchase | $5.20 | +450 | 950 | +90% | +$2,340 | ||||||
2018-11-23 | FBIO | Fortress Biotech, Inc. | Hunter Robyn | CFO | S - Sale | $1.29 | -20,370 | 239,759 | -8% | -$26,277 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |